专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO03028626A2 A METHOD OF REDUCING MORTALITY AND MORBIDITY ASSOCIATED WITH CRITICAL ILLNESSES 审中-公开
标题翻译：减少与关键伤害相关的死亡率和死亡率的方法
公开(公告)号：WO03028626A2
公开(公告)日：2003-04-10
申请号：PCT/US0228123
申请日：2002-09-19
申请人： LILLY CO ELI , EFENDIC SUAD , JAKUBOWSKI JOSEPH ANTHONY
发明人： EFENDIC SUAD , JAKUBOWSKI JOSEPH ANTHONY
IPC分类号： A61K38/26 , A61P11/00 , A61P11/08 , A61P11/16 , A61P31/04 , A61K
CPC分类号： A61K38/26
摘要： This invention relates to the use of glucagon-like peptide (GLP-1) compounds to reduce the mortality and morbidity associated with critical illnesses wherein a patient is predisposed to or suffers from some type of respiratory distress.
摘要翻译：本发明涉及胰高血糖素样肽（GLP-1）化合物在降低与患有易患某种类型的呼吸窘迫的危重疾病相关的死亡率和发病率的用途。

2. 发明申请

WO2005108982A1 METHODS FOR IDENTIFYING COMPOUNDS FOR TREATING DIABETES MELLITUS 审中-公开
标题翻译：鉴定化合物治疗糖尿病的方法
公开(公告)号：WO2005108982A1
公开(公告)日：2005-11-17
申请号：PCT/EP2005/004995
申请日：2005-05-09
申请人： BIOSTRATUM AB , EFENDIC, Suad
发明人： EFENDIC, Suad
IPC分类号： G01N33/50
CPC分类号： G01N33/507 , G01N2333/655 , G01N2333/726 , G01N2800/042
摘要： The invention is directed to methods for identifying candidate beta cell-sensitizing compounds comprising providing a pancreatic beta islet cell population derived from a diabetic subject, contacting the beta islet cell population with one or more somatostatin receptor 5-binding compounds, and identifying those somatostatin receptor 5-binding compounds that promote insulin secretion from the pancreatic beta islet cell population at a higher rate than from a control cell population. The invention is further directed to methods for treating type II diabetes comprising administering a beta cell-sensitizing compound identified by the first method of the invention to a diabetic patient in need of treatment.
摘要翻译：本发明涉及用于鉴定候选β细胞增敏化合物的方法，其包括提供衍生自糖尿病受试者的胰岛β细胞群体，使β岛细胞群与一种或多种生长抑素受体5-结合化合物接触，并鉴定那些生长抑素受体 5种结合的化合物以比来自对照细胞群体更高的速率促进胰岛β细胞群体的胰岛素分泌。本发明还涉及用于治疗II型糖尿病的方法，包括将由本发明的第一种方法鉴定的β细胞增敏化合物给予需要治疗的糖尿病患者。

3. 发明申请

WO0016797A3 USE OF GLP-1 OR ANALOGS IN TREATMENT OF STROKE 审中-公开
标题翻译：使用GLP-1或模拟物进行治疗
公开(公告)号：WO0016797A3
公开(公告)日：2000-05-25
申请号：PCT/US9922026
申请日：1999-09-22
申请人： LILLY CO ELI , EFENDIC SUAD
发明人： EFENDIC SUAD
IPC分类号： A61K38/04 , A61K38/26 , A61P3/10 , A61P9/10 , A61P25/00
CPC分类号： A61K38/26
摘要： This invention provides a method of reducing mortality and morbidity associated with stroke. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.
摘要翻译：本发明提供了降低与中风相关的死亡率和发病率的方法。 GLP-1，GLP-1类似物或GLP-1衍生物以有效使血糖正常化的剂量施用。

4. 发明申请

WO1993018786A1 USE OF A PEPTIDE 审中-公开
标题翻译：使用肽
公开(公告)号：WO1993018786A1
公开(公告)日：1993-09-30
申请号：PCT/DK1993000099
申请日：1993-03-18
申请人： NOVO NORDISK A/S , EFENDIC, Suad , GUTNIAK, Mark , KIRK, Ole
发明人： NOVO NORDISK A/S
IPC分类号： A61K37/28
CPC分类号： A61K38/26 , A61K31/175 , A61K31/445 , A61K31/64 , A61K31/155 , A61K2300/00
摘要： GLP-1(7-37), GLP-1(7-36)amide, and certain related compounds can be used to provide a medicament for use in the treatment of diabetes in a regimen which additionally comprises treatment with an oral hypoglycaemic agent. A strong synergistic effect is observed.
摘要翻译： GLP-1（7-37），GLP-1（7-36）酰胺和某些相关化合物可用于提供一种用于治疗糖尿病的药物，其另外包括用口服降糖药治疗。观察到强烈的协同效应。

5. 发明申请

WO2009109647A1 METHOD FOR MONITORING A METABOLIC STATE BY MEASURING INOSITOL PHOSPHATE 审中-公开
标题翻译：通过测量磷酸氢钠监测代谢状态的方法
公开(公告)号：WO2009109647A1
公开(公告)日：2009-09-11
申请号：PCT/EP2009/052645
申请日：2009-03-05
申请人： NORSTEDT, Gunnar , TOLLET EGNELL, Petra , MORITZ, Thomas , EFENDIC, Suad
发明人： NORSTEDT, Gunnar , TOLLET EGNELL, Petra , MORITZ, Thomas , EFENDIC, Suad
IPC分类号： G01N33/50 , G01N33/577
CPC分类号： G01N33/6893 , C07K16/44 , G01N2800/042
摘要： A method of monitoring the metabolic state in a mammal, comprising obtaining a test sample from the mammal and measuring the amount of inositol phosphate in the sample. A kit for use in such a method.
摘要翻译：一种监测哺乳动物代谢状态的方法，包括从哺乳动物获得测试样品并测量样品中磷酸肌醇的量。用于这种方法的试剂盒。

6. 发明申请

WO2003028626A3 GLUCAGON-LIKE PEPTIDES (GLP-1) AND TREATMENT OF RESPIRATORY DISTRESS 审中-公开
公开(公告)号：WO2003028626A3
公开(公告)日：2003-04-10
申请号：PCT/US2002/028123
申请日：2002-09-19
申请人： ELI LILLY AND COMPANY , EFENDIC, Suad , JAKUBOWSKI, Joseph, Anthony
发明人： EFENDIC, Suad , JAKUBOWSKI, Joseph, Anthony
IPC分类号： A61K38/00
摘要： This invention relates to the use of glucagon-like peptide (GLP-1) compounds to reduce the mortality and morbidity associated with critical illnesses wherein a patient is predisposed to or suffers from some type of respiratory distress.

7. 发明申请

WO9963976A3 LIVER-SELECTIVE GLUCOCORTICOID ANTAGONIST FOR TREATING DIABETES 审中-公开
标题翻译：用于治疗糖尿病的肝脏选择性GLUCOCORTICOID ANTAGONIST
公开(公告)号：WO9963976A3
公开(公告)日：2001-12-20
申请号：PCT/IB9901175
申请日：1999-06-07
申请人： KAROBIO AB , APELQVIST THERESA , EFENDIC SUAD
发明人： APELQVIST THERESA , EFENDIC SUAD
IPC分类号： A61K45/00 , A61K31/00 , A61K31/155 , A61K31/192 , A61K31/426 , A61K31/64 , A61K38/28 , A61K45/06 , A61P3/10 , A61P43/00 , C07C57/58 , A61K31/19
CPC分类号： A61K31/00
摘要： Use of a liver-selective glucocorticoid antagonist, preferably the compound having formula (I) in the preparation of a pharmaceutical composition for the treatment of diabetes. A composition for the treatment of diabetes containing such a glucocorticoid antagonist, and a method of treating diabetes using the composition.
摘要翻译：使用肝选择性糖皮质激素拮抗剂，优选具有式（I）的化合物在制备用于治疗糖尿病的药物组合物中。用于治疗含有这种糖皮质激素拮抗剂的糖尿病的组合物，以及使用该组合物治疗糖尿病的方法。

8. 发明申请

WO9941411A3 METHOD FOR DIAGNOSIS AND TREATMENT OF DISORDERS OF CARBOHYDRATE METABOLISM 审中-公开
标题翻译：诊断和治疗碳水化合物代谢紊乱的方法
公开(公告)号：WO9941411A3
公开(公告)日：1999-09-30
申请号：PCT/SE9900177
申请日：1999-02-11
申请人： EFENDIC SUAD
发明人： EFENDIC SUAD
IPC分类号： A01K67/027 , A61K45/00 , A61P3/08 , A61P5/50 , A61P43/00 , C12N5/10 , C12N9/88 , C12N15/09 , C12N15/85 , C12Q1/68
CPC分类号： C12Q1/6883 , A01K2217/05 , A01K2217/075 , A01K2267/0306 , A01K2267/0362 , A01K2267/0393 , C12N9/88 , C12N15/8509 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates to a method of detecting a disorder in carbohydrate metabolism, such as type II diabetes (NIDDM), by detecting a promoter of an adenylate cyclase III gene, the promoter having enhanced activity. The present invention also relates to a promoter from an adenylate cyclase III gene having enhanced activity, and isolated DNA molecules containing this promoter. The promoter having enhanced activity can be part of a transgenic animal. In another embodiment, the invention relates to a method of treating a patient having a disorder in carbohydrate metabolism, such as type II diabetes (NIDDM), and a method of enhancing or restoring a patient's response to insulin. Each of these methods includes administering to the patient a down regulator, an antagonist, or an inhibitor of expression of the adenylate cyclase III gene, or of the activity of one of its gene products.
摘要翻译：本发明涉及通过检测腺苷酸环化酶III基因的启动子来检测碳水化合物代谢紊乱如II型糖尿病（NIDDM）的方法，所述启动子具有增强的活性。本发明还涉及来自具有增强的活性的腺苷酸环化酶III基因的启动子和含有该启动子的分离的DNA分子。具有增强的活性的启动子可以是转基因动物的一部分。在另一个实施方案中，本发明涉及治疗患有糖代谢障碍例如II型糖尿病（NIDDM）的患者的方法，以及增强或恢复患者对胰岛素的应答的方法。这些方法中的每一种都包括向患者施用腺病毒环化酶III基因的下调，拮抗剂或表达抑制剂或其基因产物之一的活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式